Biotech

CEO Will Knox has taken the unusual step of scaling back the startup’s IPO by $10 million to dodge ‘fast money’ investors that lack understanding of the business.

The sale of 23andMe's genetic database to Regeneron shows gaps in Australia's cross-border data protection laws for sensitive health information.

PolyActiva is taking its high-precision glaucoma implant to global trials in a test for Australia’s biotech ambitions.

Despite world-class research, Australia’s funding structures and risk-averse capital are choking innovation before it ever reaches market.

Levur’s breakthrough yeast fermentation tech aims to deliver sustainable, high-value oils for cosmetics and food, cutting palm oil’s environmental cost.

Tariffs, FDA cuts and NIH turmoil are reshaping global pharma. Australia’s life sciences sector sees risk — but also a rare chance to gain ground.

The faecal transplant startup is raising $4m to develop a product for the US — but America’s regulatory environment in the era of DOGE and RFK is becoming increasingly unclear.